NasdaqGS:MGNXBiotechs
MacroGenics (MGNX) Quarterly Loss Of US$36.8 Million Tests Bullish Path To Profitability
MacroGenics (MGNX) has opened Q1 2026 with revenue of about US$20.8 million and a basic EPS loss of roughly US$0.58, while trailing twelve month figures sit at revenue of about US$157.1 million and a basic EPS loss of around US$1.11. Over recent quarters, the company has reported revenue between US$13.2 million and US$72.8 million, with quarterly EPS ranging from a profit of about US$0.27 to losses such as US$0.65. This update keeps the focus on how the company is scaling revenue relative to...